Zolymbus

(Bimatoprost)

ApprovedSmall molecule

Zolymbus is a small molecule that works as a Prostanoid FP Receptor Agonist.[2] It is being used across 16 indications, with its most advanced program in Approved.[1]

Zolymbus is one of 301 small molecule programs targeting Hypertrichosis. It is currently in Approved.

Indications

Total Trials

Active Trials

300

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

HypertrichosisActive, not recruiting

Alzheimer DiseaseActive, not recruiting

AlopeciaActive, not recruiting

Hypotrichosis SimplexActive, not recruiting

CataractActive, not recruiting

DermatochalasisApproved

Alopecia AreataApproved

Thyroid Eye DiseaseActive, not recruiting

Breast CancerActive, not recruiting

GrowthActive, not recruiting

HypertrichosisPreclinical

Active, not recruiting

Alzheimer DiseasePreclinical

Active, not recruiting

AlopeciaApproved

Active, not recruiting

Hypotrichosis SimplexApproved

Active, not recruiting

CataractPreclinical

Active, not recruiting

DermatochalasisApproved

Approved

Alopecia AreataApproved

Approved

Thyroid Eye DiseaseApproved

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zolymbus

AbbVie

Approved

1 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Voltaren

Novartis

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 1Recruiting

Graves Ophthalmopathy

NCT03708627

Clinical

Trials by Indication[1]

Ocular Hypertension14 trials

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Completed· AbbVie logo

AbbVie··NCT01853085·1,830 enrolled

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT04285580·37 enrolled

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT02250651·528 enrolled

Show 11 more trials

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT02247804·594 enrolled

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT02636946·144 enrolled

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT02507687·240 enrolled

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 2·NCT01291108·125 enrolled

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

Completed·IInnovative Medical·Phase 4·NCT00348062

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT03850782·515 enrolled

Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 2/3·NCT00300443·561 enrolled

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Completed·FForSight Vision5, Inc.·Phase 2·NCT01915940·169 enrolled

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

Completed·FForSight Vision5, Inc.·Phase 1/2·NCT02742649·55 enrolled

A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie··NCT01646151·2,580 enrolled

24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension

Completed·UUniversity of Parma·Phase 4·NCT01655758·61 enrolled

Glaucoma3 trials

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Completed·LLaboratoires Thea·Phase 3·NCT05397600·684 enrolled

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

Unknown status·—·Phase 4·NCT04981886·115 enrolled

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Completed·LLaboratoires Thea·Phase 3·NCT03825380·485 enrolled

ESS2 trials

Expanded Access to Bimatoprost (Durysta)

No longer available· AbbVie logo

AbbVie··NCT05338606

Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures

Completed·UUniversity of Milan·Phase 3·NCT02154217·200 enrolled

Hypotrichosis2 trials

Bimatoprost for the Treatment of Eyebrow Hypotrichosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01765764·357 enrolled

Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo

Completed·KKenneth Beer·Phase 4·NCT01387906·20 enrolled

Treatment1 trial

Treatment of Hypopigmented Scars With Bimatoprost

Recruiting·MMedstar Health Research Institute·Phase 2·NCT06122090·25 enrolled

14 more indications

Migraine1 trial

Topical Bimatoprost in the Treatment of Migraine

Unknown status·MManistee Partners·Phase 2·NCT03419715·70 enrolled

Breast Cancer1 trial

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Withdrawn·JJonsson Comprehensive Cancer Center·N/A·NCT00999557

Systemic1 trial

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Completed·LLaboratoires Thea·Phase 1·NCT05729594·40 enrolled

Growth1 trial

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

Completed·UUniversity of Miami·N/A·NCT00773136·21 enrolled

Alopecia Areata1 trial

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Completed·UUniversity of California, San Francisco·N/A·NCT00187577·14 enrolled

Vitiligo1 trial

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment

Completed·MMedical University of South Carolina·Phase 1·NCT04738149·4 enrolled

Androgenetic Alopecia1 trial

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Terminated· AbbVie logo

AbbVie·Phase 1·NCT02676310·53 enrolled

Thyroid Eye Disease1 trial

Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)

Completed·—·Phase 4·NCT02059655·31 enrolled

Skin Pigmentation1 trial

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Completed·—·Phase 4·NCT00705757·89 enrolled

CLE1 trial

Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

Completed·—·Phase 2·NCT02170662·33 enrolled

Function1 trial

Stop Retinal Ganglion Cell Dysfunction Study

Terminated·UUniversity of Miami·Phase 3·NCT02390284·28 enrolled

Graves ophthalmopathy1 trial

The Role of Bimatoprost in Graves' Periorbitopathy

Recruiting·JJohns Hopkins University·Phase 1·NCT03708627·3 enrolled

Open-Angle Glaucoma1 trial

An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·Phase 3·NCT03891446·455 enrolled

Unspecified4 trials

An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product

Completed·FForSight Vision5, Inc.·Phase 2·NCT02143843·75 enrolled

Dose-Ranging Study of the Bimatoprost Ocular Insert

Completed·FForSight Vision5, Inc.·Phase 2·NCT02358369·156 enrolled

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Completed·FForSight Vision5, Inc.·Phase 2·NCT02537015·81 enrolled

Show 1 more trial

Bimatoprost Ocular Insert Pharmacokinetic Study

Completed·FForSight Vision5, Inc.·Phase 1·NCT02444767·11 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 16, 2001

LUMIGAN

NDA NDA021275

Dec 24, 2008

LATISSE

NDA NDA022369

Aug 31, 2010

LUMIGAN

NDA NDA022184

Mar 4, 2020

DURYSTA

NDA NDA211911

Sep 9, 2025

ZOLYMBUS

NDA NDA217307

Sources

References

[1]
ClinicalTrials.gov — 39 trial records for Bimatoprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bimatoprost compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bimatoprost. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA217307). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Zolymbus. U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Prostanoid FP Receptor Agonist[2]
Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

Patent Landscape[5]

Patent Cliff

Dec 19, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9149428Dec 19, 2026

10441543Dec 19, 2026

8206737Apr 7, 2027

7851504Jun 13, 2027

7799336Apr 24, 2029

4 more patents

8629185Jul 15, 2031

9492316Oct 31, 2034

9980974Oct 31, 2034

10314780Jun 8, 2036

Zolymbus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Ocular Hypertension14 trials

Glaucoma3 trials

ESS2 trials

Hypotrichosis2 trials

Treatment1 trial

Migraine1 trial

Breast Cancer1 trial

Systemic1 trial

Growth1 trial

Alopecia Areata1 trial

Vitiligo1 trial

Androgenetic Alopecia1 trial

Thyroid Eye Disease1 trial

Skin Pigmentation1 trial

CLE1 trial

Function1 trial

Graves ophthalmopathy1 trial

Open-Angle Glaucoma1 trial

Unspecified4 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News